Cargando…

Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation

BACKGROUND & AIMS: The incidence of primary liver cancer (PLC) is increasing in Western Europe. To understand trends over time and the current burden in the UK, a detailed analysis of the epidemiology of PLC and its subtypes was conducted. METHODS: Data on PLCs diagnosed during 1997–2017 were ob...

Descripción completa

Detalles Bibliográficos
Autores principales: Burton, Anya, Tataru, Daniela, Driver, Robert J., Bird, Thomas G., Huws, Dyfed, Wallace, David, Cross, Timothy J.S., Rowe, Ian A., Alexander, Graeme, Marshall, Aileen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966867/
https://www.ncbi.nlm.nih.gov/pubmed/33748727
http://dx.doi.org/10.1016/j.jhepr.2021.100232
_version_ 1783665753210224640
author Burton, Anya
Tataru, Daniela
Driver, Robert J.
Bird, Thomas G.
Huws, Dyfed
Wallace, David
Cross, Timothy J.S.
Rowe, Ian A.
Alexander, Graeme
Marshall, Aileen
author_facet Burton, Anya
Tataru, Daniela
Driver, Robert J.
Bird, Thomas G.
Huws, Dyfed
Wallace, David
Cross, Timothy J.S.
Rowe, Ian A.
Alexander, Graeme
Marshall, Aileen
author_sort Burton, Anya
collection PubMed
description BACKGROUND & AIMS: The incidence of primary liver cancer (PLC) is increasing in Western Europe. To understand trends over time and the current burden in the UK, a detailed analysis of the epidemiology of PLC and its subtypes was conducted. METHODS: Data on PLCs diagnosed during 1997–2017 were obtained from population-based, nationwide registries in the UK. European age-standardised incidence (ASR) and incidence-based mortality rates (ASMR) per 100,000 person-years were calculated overall and by sex and UK-nation. Annual percentage change in rates was estimated using Joinpoint regression. One-, 2-, and 5-year age-standardised net survival was estimated. RESULTS: A total of 82,024 PLCs were diagnosed. Both hepatocellular carcinoma (HCC) incidence and mortality rates trebled (ASR 1.8–5.5 per 100,000, ASMR 1.3–4.0). The rate of increase appeared to plateau around 2014/2015. Scottish men consistently had the highest HCC incidence rates. PLC survival increased, driven by a substantial increase in the proportion that are HCC (as prognosis is better than other PLCs) and in HCC survival (change in 1-year survival 24–47%). Intrahepatic cholangiocarcinoma was the most common PLC in women and 1-year survival improved from 22.6% to 30.5%. CONCLUSIONS: PLC incidence has been increasing rapidly but, as most risk factors are modifiable, it is largely a preventable cancer. This rate of increase has slowed in recent years, possibly attributable to effective treatment for hepatitis C. As other risk factors such as obesity and diabetes remain prevalent in the UK, it is unlikely the considerable burden of this disease will abate. While improvements in survival have been made, over half of patients are not alive after 1 year, therefore further progress in prevention, early detection, and treatment innovation are needed. LAY SUMMARY: Many more people are getting liver cancer, particularly the subtype hepatocellular carcinoma, than 20 years ago. Men in Scotland are most likely to get liver cancer and to die from it. Survival after liver cancer diagnosis is getting longer but still less than half are alive after 1 year.
format Online
Article
Text
id pubmed-7966867
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-79668672021-03-19 Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation Burton, Anya Tataru, Daniela Driver, Robert J. Bird, Thomas G. Huws, Dyfed Wallace, David Cross, Timothy J.S. Rowe, Ian A. Alexander, Graeme Marshall, Aileen JHEP Rep Research Article BACKGROUND & AIMS: The incidence of primary liver cancer (PLC) is increasing in Western Europe. To understand trends over time and the current burden in the UK, a detailed analysis of the epidemiology of PLC and its subtypes was conducted. METHODS: Data on PLCs diagnosed during 1997–2017 were obtained from population-based, nationwide registries in the UK. European age-standardised incidence (ASR) and incidence-based mortality rates (ASMR) per 100,000 person-years were calculated overall and by sex and UK-nation. Annual percentage change in rates was estimated using Joinpoint regression. One-, 2-, and 5-year age-standardised net survival was estimated. RESULTS: A total of 82,024 PLCs were diagnosed. Both hepatocellular carcinoma (HCC) incidence and mortality rates trebled (ASR 1.8–5.5 per 100,000, ASMR 1.3–4.0). The rate of increase appeared to plateau around 2014/2015. Scottish men consistently had the highest HCC incidence rates. PLC survival increased, driven by a substantial increase in the proportion that are HCC (as prognosis is better than other PLCs) and in HCC survival (change in 1-year survival 24–47%). Intrahepatic cholangiocarcinoma was the most common PLC in women and 1-year survival improved from 22.6% to 30.5%. CONCLUSIONS: PLC incidence has been increasing rapidly but, as most risk factors are modifiable, it is largely a preventable cancer. This rate of increase has slowed in recent years, possibly attributable to effective treatment for hepatitis C. As other risk factors such as obesity and diabetes remain prevalent in the UK, it is unlikely the considerable burden of this disease will abate. While improvements in survival have been made, over half of patients are not alive after 1 year, therefore further progress in prevention, early detection, and treatment innovation are needed. LAY SUMMARY: Many more people are getting liver cancer, particularly the subtype hepatocellular carcinoma, than 20 years ago. Men in Scotland are most likely to get liver cancer and to die from it. Survival after liver cancer diagnosis is getting longer but still less than half are alive after 1 year. Elsevier 2021-01-19 /pmc/articles/PMC7966867/ /pubmed/33748727 http://dx.doi.org/10.1016/j.jhepr.2021.100232 Text en Crown Copyright © 2021 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Article
Burton, Anya
Tataru, Daniela
Driver, Robert J.
Bird, Thomas G.
Huws, Dyfed
Wallace, David
Cross, Timothy J.S.
Rowe, Ian A.
Alexander, Graeme
Marshall, Aileen
Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation
title Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation
title_full Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation
title_fullStr Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation
title_full_unstemmed Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation
title_short Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation
title_sort primary liver cancer in the uk: incidence, incidence-based mortality, and survival by subtype, sex, and nation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966867/
https://www.ncbi.nlm.nih.gov/pubmed/33748727
http://dx.doi.org/10.1016/j.jhepr.2021.100232
work_keys_str_mv AT burtonanya primarylivercancerintheukincidenceincidencebasedmortalityandsurvivalbysubtypesexandnation
AT tatarudaniela primarylivercancerintheukincidenceincidencebasedmortalityandsurvivalbysubtypesexandnation
AT driverrobertj primarylivercancerintheukincidenceincidencebasedmortalityandsurvivalbysubtypesexandnation
AT birdthomasg primarylivercancerintheukincidenceincidencebasedmortalityandsurvivalbysubtypesexandnation
AT huwsdyfed primarylivercancerintheukincidenceincidencebasedmortalityandsurvivalbysubtypesexandnation
AT wallacedavid primarylivercancerintheukincidenceincidencebasedmortalityandsurvivalbysubtypesexandnation
AT crosstimothyjs primarylivercancerintheukincidenceincidencebasedmortalityandsurvivalbysubtypesexandnation
AT roweiana primarylivercancerintheukincidenceincidencebasedmortalityandsurvivalbysubtypesexandnation
AT alexandergraeme primarylivercancerintheukincidenceincidencebasedmortalityandsurvivalbysubtypesexandnation
AT marshallaileen primarylivercancerintheukincidenceincidencebasedmortalityandsurvivalbysubtypesexandnation
AT primarylivercancerintheukincidenceincidencebasedmortalityandsurvivalbysubtypesexandnation